Advances in the Relationship between Human Papillomavirus Infection and Lung Cancer

2018 ◽  
Vol 08 (09) ◽  
pp. 819-824
Author(s):  
晓玥 戴
2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Yuejuan Liang ◽  
Mengjie Chen ◽  
Lu Qin ◽  
Bing Wan ◽  
He Wang

In the original publication of this article [1] there was an error in the results section of the article.


2018 ◽  
Vol 14 ◽  
pp. 174550651880564 ◽  
Author(s):  
Mohamed Akaaboune ◽  
Bruno Kenfack ◽  
Manuela Viviano ◽  
Liliane Temogne ◽  
Rosa Catarino ◽  
...  

Objective: Persistent infection with human papillomavirus is the prerequisite for the development of cervical precancerous and cancerous lesions. The aim of this study was to determine the time-to-viral clearance in a population of human papillomavirus–infected Cameroonian women and to examine the possible predictors of viral persistence. Methods: We conducted a prospective cohort study based on a population of human papillomavirus–positive women having previously been recruited in a self-human papillomavirus-based cervical cancer screening campaign, who were invited for a control visit at 6 and 12 months. We determined human papillomavirus clearance using self-sampling (Self-HPV) and physician-sampling (Dr-HPV), which were analyzed with a point-of-care assay (GeneXpert® IV; Cepheid, Sunnyvale, CA, USA). Logistic regression was performed to assess the relationship between sociodemographic and clinical characteristics with HPV clearance according to the two sampling techniques. Results: A total of 187 participants were included in the study. At the 12 months follow-up, 79.5% (n = 104) and 65.3% (n = 86) had cleared their human papillomavirus infection according to Dr-HPV and self-HPV, respectively (p = 0.001). Only parity (>5 children) was statistically associated with viral persistence (p = 0.033). According to Dr-HPV, clearance of women treated with thermoablation at 12 months was of 84.1% versus 70.2% for non-treated women (p = 0.075). Conclusion: The human papillomavirus clearing rates found in our study are close to those found in other studies worldwide. Parity was significantly associated with human papillomavirus persistence. Larger, prospective studies are needed to confirm our results.


Medicine ◽  
2016 ◽  
Vol 95 (23) ◽  
pp. e3856 ◽  
Author(s):  
Frank Cheau-Feng Lin ◽  
Jing-Yang Huang ◽  
Stella Ching-Shao Tsai ◽  
Oswald Ndi Nfor ◽  
Ming-Chih Chou ◽  
...  

Author(s):  
Matvey M. Tsyganov ◽  
A. M. Pevsner ◽  
M. K. Ibragimova ◽  
I. V. Deryusheva ◽  
N. V. Litviakov

This review is devoted to assessing the world’s prevalence of human papillomavirus (HPV) in lung cancer (LC), which is recognized as the etiological factor of cervical cancer. However, data show that this virus is presents not only in gynecological carcinomas, but also in tumors of other organs, in particular, the upper respiratory tract and the digestive tract. The review includes 54 articles. Of all the studies analyzed, 10 of them showed a complete absence of HPV in the biological material in patients with LC. The highest percentage of HPV occurrence by region is observed in Australia, Latin America, followed by the Asian region. Interestingly, the highest occurrence of high oncogenic types (16 and 18) is observed in Asia (35.4%), then in Latin America (33.6%) and Europe (23.6%). Low oncogenic types (6 and 11) are mainly observed in Asia (40.0%). This review is the first such study in Russia. However, the frequency of occurrence of HPV in lung tumor tissue highly variety. This may raise the question of whether HPV really plays a role in the carcinogenesis of lung cancer, which makes further research in this area relevant and promising.


Sign in / Sign up

Export Citation Format

Share Document